Advances in Hyperkalemia Management: Implications for Patients and Providers
PROGRAM OVERVIEW
Conventional treatment of hyperkalemia is restricted by adverse events, as well as a dearth of evidence supporting clinical use (specifically with sodium polystyrene sulfonate). For medication-induced hyperkalemia, treatment involves a dose decrease or discontinuation of the offending agent (usually a renin-angiotensin-aldosterone system inhibitor [RAASI]); however, this often prevents patients from receiving appropriate guideline-directed management. Recent research has led to the development of two novel potassium binders with good safety profiles that allow patients to maintain or increase the use of RAASIs for cardio- and reno-protection.
This CME activity, Advances in Hyperkalemia Management: Implications for Patients and Providers, will help participating clinicians identify those patient populations most likely to present with or develop hyperkalemia, and utilize the appropriate conventional and/or novel agents to correct subacute hyperkalemia.
AGENDA
- Welcome and Introductions
- Understanding the Current Subacute/Chronic Hyperkalemia Armamentarium
- Improving the Care of Adults with and at Risk for Hyperkalemia
- Q&A Session and Activity Roundup
TARGET AUDIENCE
This activity is intended for physicians, hospitalists, nephrologists, and cardiologists involved in the management and education of adults with or at risk for hyperkalemia.
EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants should be able to demonstrate the ability to:
- Compare and contrast safety and efficacy data on novel and conventional agents for correcting subacute/chronic hyperkalemia
- Identify patient populations likely to present with or develop hyperkalemia
- Incorporate novel agents for correcting subacute hyperkalemia into patient care plans
ACCREDITATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of MedChi, The Maryland State Medical Society, and Rockpointe. MedChi is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
MedChi designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit or the evaluation, please email fberry@medchi.org.
ABIM MOC DESIGNATION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through MedChi’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
FACULTY
INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME/CE CREDIT
PROVIDER
Jointly provided by MedChi and Rockpointe
SUPPORTER
RELATED COURSES

Credits 1.00 (60 min)
Format Webcourse

Credits 1.00 (60 min)
Format Webcourse

Credits 1.00 (60 min)
Format Webcourse
Oct